M蛋白相关性杆状体肌病3例及文献回顾

doi:10.6040/j.issn.1671-7554.0.2022.0084

摘要/Abstract

摘要： 目的对3例怀疑M蛋白相关性杆状体肌病患者进行肌肉病理检查、M蛋白筛查明确诊断,提高对这一罕见疾病的认识并探讨对此疾病的诊疗方案。方法报道3例M蛋白相关性杆状体肌病,结合文献复习对病例特点进行总结。结果 3例患者均表现为进行性加重的肌肉无力症状,完善肌肉活检诊断为杆状体肌病,合并M蛋白,给予行自体造血干细胞移植治疗有效。结论散发的晚发型成人杆状体肌病是一种罕见的、亚急性进展的肌病,常合并M蛋白,针对清除M蛋白的治疗是有效的。

关键词: M蛋白, 杆状体肌病, 自体造血干细胞移植

Abstract: Objective Three patients suspected of sporadic late-onset nemaline myopathy with monoclonal gammopathy were diagnosed by muscle pathological examination and monoclonal protein screening, so as to improve the understanding of this rare disease and explore its diagnosis and treatment. Methods The characteristics of this disease were summarized and relevant literatures were reviewed. Results All of the 3 patients presented with progressively aggravated muscle weakness, which was diagnosed by muscle biopsy as sporadic late-onset nemaline myopathy with monoclonal gammopathy. Autologous hematopoietic stem cell transplantation was effective. Conclusion Sporadic late-onset nemaline myopathy is a rare, subacute progressive myopathy characterized by proximal muscle weakness and atrophy, often complicated with monoclonal gammopathy. Therapies directed at eradication of M protein are effective.

Key words: Monoclonal gammopathy, Sporadic late-onset nemaline myopathy, Autologous hematopoietic stem cell transplantation

中图分类号:

R746.9

董文灏,赵冰, 李召, 张琛,袁成录. M蛋白相关性杆状体肌病3例及文献回顾[J]. 山东大学学报 (医学版), 2022, 60(10): 74-81.

DONG Wenhao, ZHAO Bing, LI Zhao, ZHANG Chen, YUAN Chenglu. Three cases of sporadic late-onset nemaline myopathy with monoclonal gammopathy and literature review[J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 74-81.

参考文献

[1] Tanboon J, Uruha A, Arahata Y, et al. Inflammatory features in sporadic late-onset nemaline myopathy are independent from monoclonal gammopathy[J]. Brain Pathol, 2021, 31(3): e12962. doi: 10.1111/bpa.12962.
[2] Uruha A, Benveniste O. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance[J]. Curr Opin Neurol, 2017, 30(5): 457-463.
[3] Chahin N, Selcen D, Engel AG. Sporadic late onset nemaline myopathy[J]. Neurology, 2005, 65(8): 1158-1164.
[4] Belhomme N, Maamar A, Le Gallou T, et al. Rare myopathy associated to MGUS, causing heart failure and responding to chemotherapy[J]. Ann Hematol, 2017, 96(4): 695-696.
[5] Schnitzler LJ, Schreckenbach T, Nadaj-Pakleza A, et al. Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases[J]. Orphanet J Rare Dis, 2017, 12(1): 86.
[6] Berentsen S, Ulvestad E, Langholm R, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients[J]. Haematologica, 2006, 91(4): 460-466.
[7] Daoud MS, Lust JA, Kyle RA, et al. Monoclonal gammopathies and associated skin disorders[J]. J Am Acad Dermatol, 1999, 40(4): 507-535.
[8] Leung N, Bridoux F, Hutchison CA, et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant[J]. Blood, 2012, 120(22): 4292-4295.
[9] Fermand JP, Bridoux F, Kyle RA, et al. How I treat monoclonal gammopathy of renal significance(MGRS)[J]. Blood, 2013, 122(22): 3583-3590.
[10] Eskazan A E, Gunduz A. What is the best treatment approach for sporadic late-onset nemaline myopathy associated with “monoclonal gammopathy of neurological significance”?[J]. Int J Cancer, 2021, 148(11): 2638-2639.
[11] Van De Donk NW, Palumbo A, Johnsen HE, et al. The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network[J]. Haematologica, 2014, 99(6): 984-996.
[12] Naddaf E, Milone M, Kansagra A, et al. Sporadic late-onset nemaline myopathy: Clinical spectrum, survival, and treatment outcomes [J]. Neurology, 2019, 93(3): e298-e305.
[13] Voermans NC, Minnema M, Lammens M, et al. Sporadic late-onset nemaline myopathy effectively treated by melphalan and stem cell transplant[J]. Neurology, 2008, 71(7): 532-534.
[14] Voermans NC, Benveniste O, Minnema MC, et al. Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCT[J]. Neurology, 2014, 83(23): 2133-2139.
[15] 张包静子, 岳冬曰, 高名士,等成人晚发型杆状体肌病合并单克隆丙种球蛋白病1例报道及文献复习[J]. 中国临床神经科学, 2015, 23(5): 509-515.
[16] Kotchetkov R, Susman D, Bhutani D, et al. Chemotherapy-based approach is the preferred treatment for sporadic late-onset nemaline myopathy with a monoclonal protein[J]. Int J Cancer, 2021, 148(11): 2807-2814.
[17] Benveniste O, Laforet P, Dubourg O, et al. Stem cell transplantation in a patient with late-onset nemaline myopathy and gammopathy[J]. Neurology, 2008, 71(7): 531-532.
[18] Milone M, Katz A, Amato AA, et al. Sporadic late onset nemaline myopathy responsive to IVIg and immunotherapy[J]. Muscle Nerve, 2010, 41(2): 272-276.
[19] Novy J, Rosselet A, Spertini O, et al. Chemotherapy is successful in sporadic late onset nemaline myopathy(SLONM)with monoclonal gammopathy[J]. Muscle Nerve, 2010, 41(2): 286-287.
[20] Doppler K, Knop S, Einsele H, et al. Sporadic late onset nemaline myopathy and immunoglobulin deposition disease[J]. Muscle Nerve, 2013, 48(6): 983-988.
[21] Montagnese F, Portaro S, Musumeci O, et al. Sporadic late-onset nemaline myopathy in a woman with multiple myeloma successfully treated with lenalidomide/dexamethasone[J]. Muscle Nerve, 2015, 51(6): 934-935.
[22] Maeda MH, Ohta H, Izutsu K, et al. Sporadic late-onset nemaline myopathy as a rare cause of slowly progressive muscle weakness with young adult onset[J]. Muscle Nerve, 2015, 51(5): 772-774.
[23] Belkhribchia MR, Tazi I, Louhab N, et al. Autologous stem cell transplantation in a patient with sporadic late-onset nemaline myopathy and monoclonal gammopathy: First Moroccan experience[J]. Presse Med, 2017, 46(1): 122-125.
[24] Kotchetkov R, Dyszkiewicz-Korpanty A, Kukreti V. Chemotherapy with stem cell transplantation is more effective than immunotherapy in sporadic late onset nemaline myopathy with monoclonal gammopathy[J]. Bone Marrow Transplant, 2018, 53(7): 895-899.
[25] Monforte M, Primiano G, Silvestri G, et al. Sporadic late-onset nemaline myopathy: clinical, pathology and imaging findings in a single center cohort[J]. J Neurol, 2018, 265(3): 542-551.
[26] Okhovat AA, Nilipour Y, Boostani R, et al. Sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance: Report of four patients[J]. Neuromuscul Disord, 2021, 31(1): 29-34.
[27] Broch K, Popperud T, Gude E, et al. A middle-aged man presenting with progressive heart failure, myopathy, and monoclonal gammopathy of uncertain significance[J]. JACC Case Rep, 2020, 2(5): 785-789.
[28] Truffert A, Iancu Ferfoglia R, Lobrinus JA, et al. Sporadic late onset nemaline myopathy with monoclonal gammopathy of undetermined significance: two cases with long term stability[J]. Eur J Transl Myol, 2020, 30(3): 9225.
[29] Maia T, Bergantim R, Costa H, et al. Impact of hematologic complete response in the treatment of sporadic late-onset nemaline myopathy associated with monoclonal gammopathy[J]. Clin Case Rep, 2021, 9(7): e04471. doi: 10.1002/ccr3.4471.
[30] Ando T, Sato T, Kurahashi S, et al. A case of sporadic late-onset nemaline myopathy with monoclonal gammopathy of undetermined significance: long-term observation of neurological symptoms after autologous stem-cell transplantation[J]. Nagoya J Med Sci, 2021, 83(3): 641-647.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed